Voting rights in treaties KEI Briefing Note 2024-9 November 27, 2024 Arianna Schouten, Thiru Balasubramaniam and James Love In 2024, several treaties were concluded or were being negotiated. Among the many issues debated were the articles and governance, including the… Continue Reading
Below is a short note on good news on a court case in India concerning access to risdiplam, a treatment for spinal muscular atrophy (SMA). The note is followed by a statement on the case by Third World Network (TWN),… Continue Reading
At around 6:30 PM CEST on Friday, 19 September 2025, relevant stakeholders were invited to observe the closure of the second meeting of the open-ended Intergovernmental Working Group on the WHO Pandemic Agreement and witnessed WHO Member States set an… Continue Reading
On Tuesday, 16 September 2025, Knowledge Ecology International (KEI) delivered the following opening statement at the Second meeting of the open-ended Intergovernmental Working Group on the WHO Pandemic Agreement. Second meeting of the open-ended Intergovernmental Working Group on the WHO… Continue Reading
On 20 May 2025, the World Health Assembly (WHA) adopted the WHO Pandemic Agreement “pursuant to Article 19 of the Constitution of the World Health Organization” through resolution WHA78.1. While achieving consensus on a number of fronts including pandemic prevention… Continue Reading
On July 28, 2025, Knowledge Ecology International (KEI) submitted a Freedom of Information Act request for records concerning the Food and Drug Administration (FDA) Orphan Products Grant Program. The program (administered by the FDA’s Office of Orphan Products Development (OOPD))… Continue Reading
On Thursday, 24 July 2025, the United Kingdom published the text of the Comprehensive Economic and Trade Agreement (CETA) between the United Kingdom of Great Britain and Northern Ireland and India and associated documents. The agreement consists of 30 chapters… Continue Reading
On June 2, 2025, KEI submitted comments regarding Neurala Bio being granted an exclusive license by the NIH for “c-Abl Tyrosine Kinase Inhibitory Compound Embodiments and Methods of Making and Using the Same” (90 FR 21054). KEI’s primary concern as… Continue Reading
On July 17, 2025, KEI submitted comments regarding the prospective Exclusive, Inter-Institutional Agreement-Institution Lead for the development and commercialization of engineered commensals to generate antigen-specific T and B cells (90 FR 29028), which is set to be given to CZ… Continue Reading
On July 18, 2025, KEI submitted comments regarding the prospective exclusive licensing by the NIH of “The Development of an in vivo Anti-CD19 Chimeric Antigen Receptor (CAR) for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases” (90 FR… Continue Reading